Bidil (Isosorbide Dinit/Hydralazine) Patent Expiration, LOE Window & CMS Spending
Bidil (Isosorbide Dinit/Hydralazine) by Azurity: Off-Patent Genericized (AB Competition), 2 AB generics, $947K 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Azurity |
| FDA Application & Pathway | N020727 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $947K |
| 2024 Medicare Part D Spend | $520K |
| 2024 Medicaid Spend | $428K |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 19.5% 2-yr change) |